



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 22, 2024

Raj Mehra, Ph.D.  
President and Chief Executive Officer  
Seelos Therapeutics, Inc.  
300 Park Avenue, 2nd Floor  
New York, NY 10022

**Re: Seelos Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed August 16, 2024**  
**File No. 333-281604**

Dear Raj Mehra Ph.D.:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Ron Ben-Bassat, Esq.